Sarepta Therapeutics,, Inc. Common Stock

SRPTNASDAQ • USD
16.07 USD
↗ 0.06 (0.38%)AT CLOSE (03:59 PM EST)
15.85
↘ 0.22 (1.40%)
POST MARKET (AS OF 07:53 PM EST)
Post Market
AS OF 07:53 PM EST
15.85
↘ 0.22 (1.40%)
🔴Market: CLOSED

SRPT is currently priced at $16.07. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone and a bearish Death Cross on the long-term moving averages. Valuation metrics place SRPT at a fair price relative to peers.

Technical & fundamental data as of Nov 13, 2026.

Open?$16.05
High?$16.23
Low?$15.70
Prev. Close?$16.01
Volume?1.3M
Avg. Volume?2.5M
VWAP?$16.03
Rel. Volume?0.53x
Bid / Ask
Bid?$15.80 × 200
Ask?$16.27 × 200
Spread?$0.47
Midpoint?$16.04
Valuation & Ratios
Market Cap?1.7B
Shares Out?107.2M
Float?98.3M
Float %?93.0%
P/E Ratio?116.75
P/B Ratio?1.13
EPS?$0.14
Dividend?0.00%
Ex-Dividend?N/A
RelatedEDITCTMX
News
Profile
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Employees
835
Market Cap
1.7B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
1997-06-04
Address
215 FIRST STREET
CAMBRIDGE, MA 02142
Phone: 617-274-4000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
2
Momentum?
5
Short Sent.?
50
Piotroski F-Score?3/9Weak
Altman Z-Score?-0.21Distress
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?19.64%High
Short Interest?19.3M
Days to Cover?7.8
Free Float98.3M
Avg Daily Volume2.5M
Settlement Date2026-10-30
Financial Health
Current Ratio?3.46Strong
Quick Ratio?2.13Strong
Cash Ratio?0.72Adequate
Debt/Equity?0.56Moderate
ValuationFAIRLY VALUEDvs 2 peers + S&P 500
Score
78/100
P/E?
S&P
3
116.8PRICEY▾
P/B?
Peers
100
S&P
94
1.13CHEAP▾
P/S?
Peers
100
S&P
89
0.88CHEAP▾
P/FCF?
S&P
89
9.8CHEAP▾
EV/EBITDA?
S&P
3
88.7HIGH▾
EV/Sales?
Peers
100
S&P
90
1.08CHEAP▾
Returns & Efficiency
ROE?
S&P
16
1.0%WEAK▾
ROA?
S&P
9
0.5%WEAK▾
Cash Flow & Enterprise
FCF?$176.4M
Enterprise Value?$2.1B
Fundamentals ratios updated end of day